Rogel and Blondy Center for Pancreatic Cancer

The Rogel and Blondy Center for Pancreatic Cancer at the Rogel Cancer Center supports patient care and translational research for pancreatic cancer. With more than 100 doctors, scientists, and trainees from across the University of Michigan, the Rogel and Blondy Center is gaining new insights into pancreatic cancer and translating this knowledge into treatments for our patients.

About the Rogel and Blondy Center

In 2024, Richard and Susan Rogel gave $50 million to establish the Rogel and Blondy Center for Pancreatic Cancer at the Rogel Cancer Center. The center reflects a bold vision to provide resources around a specific disease to achieve transformative impact that cannot be supported by typical grant funding. In this case, our mission is to double the survival rate for pancreatic cancer in the next 10 years. 

The center is led by Timothy Frankel, MD; Costas Lyssiotis, PhD; and Marina Pasca di Magliano, PhD.  Meet the team.

Learn more about how you can support this important research.

The Rogel and Blondy Center includes four strategic pillars

• Enhancing and expanding access to world-class patient care
• Innovating and advancing discovery and translational research
• Accelerating new treatment options through clinical research and clinical trials
• Investing in infrastructure, including a biobank and leading-edge research technologies

About pancreatic cancer

Pancreatic cancer remains one of the deadliest of the major cancers, with a five-year survival rate of only 13%. It is a complex and stealthy disease that often can’t be diagnosed until it is too difficult to treat with current therapies. 

Rogel and Blondy researchers are focused on accelerating what they learn in their laboratories to move discoveries quickly to the clinic to benefit patients.